Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes

Gene Therapy

Volumn 10, Issue 14, 2003, Pages 1189-1197

  Junker, K ^a,b   Koehl, U ^a   Zimmerman, S ^a   Stein, S ^b   Schwabe, D ^a   Klingebiel, T ^a   Grez, M ^b  

^a GOETHE UNIVERSITY   (Germany)

^b Institute for Biomedical Research   (Germany)

Author keywords

Death effector domain; Donor lymphocyte infusions; Gene transfer; HSV TK; Suicide fusion genes; T lymphocytes

Indexed keywords

BINDING PROTEIN; CD34 ANTIGEN; FAS ANTIGEN; GANCICLOVIR; MEMBRANE ANTIGEN; NERVE GROWTH FACTOR RECEPTOR; RETROVIRUS VECTOR; THYMIDINE KINASE; VIRUS VECTOR;

ALLOIMMUNITY; ARTICLE; CELL ACTIVATION; CELL DEATH; CELL KINETICS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIMERIZATION; DNA MODIFICATION; FUSION GENE; GENE CONSTRUCT; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; VIRUS MUTANT;

ANTIVIRAL AGENTS; CELL DEATH; COENZYME A LIGASES; ESCHERICHIA COLI PROTEINS; GANCICLOVIR; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE TRANSFUSION; RECEPTORS, NERVE GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; SIMPLEXVIRUS; T-LYMPHOCYTES; TACROLIMUS BINDING PROTEINS; THYMIDINE KINASE;

SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0041308270     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301977     Document Type: Article

References (39)

1. Kernan NA et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993; 328: 593-602.
2. Marks D et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first two years. Ann Intern Med 1993; 119: 207.
3. Champli R. T cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. J Hematother 1993; 2: 27.
4. Murphy WJ, Bazar BR. New strategies for preventing graft-versus-host disease. Curr Opin Immunol 1999; 11: 509-515.
5. Kolb HJ et al. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European group for blood and marrow transplantat working party chronic leukemia. Blood 1995; 86: 2041-2050.
6. Bonini C et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science 1997; 276: 1719-1724.
7. Bordignon C et al. Clinical protocol: transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo modulation of donor antitumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995; 6: 813-819.
8. Tiberghien P et al. Use of donor T lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation a phase I-II study. Hum Gene Ther 1997; 8: 615-624.
9. Link C-J et al. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. Hum Gene Ther 1998; 9: 115-134.
10. Tiberghien P et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach after bone marrow transplantation? Blood 1994; 84: 1333-1341.
11. Moolten FL, Wells JM. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1996; 46: 5276-5281.
12. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxy-guanosine 5′-triphosphate analogous: kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989; 264: 19039-19044.
13. Garin MI et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001; 97: 122-129.
14. Thomis DC et al. A fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001; 97: 1249-1257.
15. Black ME, Karkus MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001; 61: 3022-3026.
16. Black ME, Newcomb TG, Wilson H-MP, Loeb LA. Creation of drug specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996; 93: 3525-3529.
17. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
18. Fehse B et al. CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol Ther 2000; 1: 448-456.
19. Bordignon C et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995; 6: 813-819.
20. Clackson T et al. Redesigning a FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 1998; 95: 10437-1044.
21. Baum C et al. Novel retroviral vectors for efficient expression of the multidrug-resistance (mdr-1) gene in early hemotopoietic cells. J Virol 1995; 69: 7541-7547.
22. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
23. Stitz J et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1 Virology 2000; 273: 16-20.
24. Tiberghien P et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell depleted allogeneic marrow graft. Blood 2001; 97: 63-72.
25. Sauce D et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002; 99: 1165-1173.
26. Verzeletti S et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 1998; 281: 1305-1308.
27. Riddell SR et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216-223.
28. Qasim W et al. T cell transduction and suicide with an enhanced mutant thymidine kinase. Gene Therapy 2002; 9: 824-827.
29. Golumbek PT et al. Herpes simplex-1 virus thymidine kinase gene is unable to completely elimintae live, nonimmunogenic tumor cell vaccines. J Immunother 1992; 12: 224-230.
30. Fan L et al. Improved artificial death switches based on caspases and FADD. Hum Gene Ther 1999; 10: 2273-2285.
31. Suda T et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045-2050.
32. Mollereau B et al. Relationship between proliferation and susceptibility to CD95- and CD2-mediated apoptosis in stimulated primary T lymphocytes: T cells manifesting proliferative unresponsiveness are preferentally susceptible to CD95-mediated apoptosis. J Immunol 1997; 159: 2668-2677.
33. van den Brink MR et al. The extracellular signal-regulated kinase pathway is required for activation-induced cell death of T cells. J Biol Chem 1999; 274: 11178-11185.
34. Martin DA, Siegel RM, Zheng L, Lenardo MJ. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/ MACHalpha1) death signal. J Biol Chem 1998; 273: 4345-4349.
35. Hildinger M, Abel KL, Ostertag W, Baum C. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 3: 4083-408.
36. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405-1413.
37. Miller AD et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
38. AH Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assay in culture. Cancer Commun 1991; 32: 07
39. Zimmermann S et al. Four-color flow cytometric analysis for measuring cytotoxic activity of NK cells and T cells against leukemic blasts: simultaneous detection of effector, proliferation, surface marker changes and killing efficiency (submitted for publication).